重症监护病房期间他汀类药物治疗与静脉血栓栓塞发生率之间的关系:倾向评分调整分析。

IF 2.9 3区 医学 Q2 Medicine
Shmeylan A Al Harbi, Mohammad Khedr, Hasan M Al-Dorzi, Haytham M Tlayjeh, Asgar H Rishu, Yaseen M Arabi
{"title":"重症监护病房期间他汀类药物治疗与静脉血栓栓塞发生率之间的关系:倾向评分调整分析。","authors":"Shmeylan A Al Harbi,&nbsp;Mohammad Khedr,&nbsp;Hasan M Al-Dorzi,&nbsp;Haytham M Tlayjeh,&nbsp;Asgar H Rishu,&nbsp;Yaseen M Arabi","doi":"10.1186/2050-6511-14-57","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients.</p><p><strong>Methods: </strong>This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables.</p><p><strong>Results: </strong>Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P=0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P=0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P=0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P=0.94).</p><p><strong>Conclusion: </strong>Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials.</p>","PeriodicalId":48846,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"14 ","pages":"57"},"PeriodicalIF":2.9000,"publicationDate":"2013-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/2050-6511-14-57","citationCount":"2","resultStr":"{\"title\":\"The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis.\",\"authors\":\"Shmeylan A Al Harbi,&nbsp;Mohammad Khedr,&nbsp;Hasan M Al-Dorzi,&nbsp;Haytham M Tlayjeh,&nbsp;Asgar H Rishu,&nbsp;Yaseen M Arabi\",\"doi\":\"10.1186/2050-6511-14-57\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients.</p><p><strong>Methods: </strong>This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables.</p><p><strong>Results: </strong>Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P=0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P=0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P=0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P=0.94).</p><p><strong>Conclusion: </strong>Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials.</p>\",\"PeriodicalId\":48846,\"journal\":{\"name\":\"BMC Pharmacology & Toxicology\",\"volume\":\"14 \",\"pages\":\"57\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2013-11-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/2050-6511-14-57\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Pharmacology & Toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/2050-6511-14-57\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/2050-6511-14-57","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

摘要

背景:研究表明他汀类药物对炎症和凝血有多效作用;这可能会影响发生静脉血栓栓塞(VTE)的风险。本研究的目的是评估重症监护病房(ICU)期间他汀类药物治疗与危重患者静脉血栓栓塞发生率之间的关系。方法:这是一项前瞻性观察队列研究的事后分析,研究对象是2006年7月至2008年1月在一家三级医疗中心重症监护病房住院的患者。主要终点是ICU住院30天内静脉血栓栓塞的发生率。次要终点是30天住院总死亡率。倾向评分用于调整临床和统计相关变量。结果:纳入原始研究的798例患者中,123例(15.4%)患者在ICU住院期间接受了他汀类药物治疗。静脉血栓栓塞风险的生存分析显示,他汀类药物治疗与静脉血栓栓塞发生率的降低无关(粗风险比(HR) 0.66, 95%可信区间(CI) 0.28-1.54, P=0.33;校正风险比(HR) 0.63, 95% CI 0.25-1.57, P=0.33)。此外,住院死亡率的生存分析显示,他汀类药物治疗与住院死亡率的降低无关(粗风险比1.26,95% CI 0.95-1.68, P=0.10,校正风险比0.98,95% CI 0.72-1.36, P=0.94)。结论:我们的研究显示他汀类药物治疗与危重患者静脉血栓栓塞风险之间无统计学意义的关联。这个问题需要在随机对照试验中进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis.

The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis.

The association between statin therapy during intensive care unit stay and the incidence of venous thromboembolism: a propensity score-adjusted analysis.

Background: Studies have shown that statins have pleiotropic effects on inflammation and coagulation; which may affect the risk of developing venous thromboembolism (VTE). The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) stay and the incidence of VTE in critically ill patients.

Methods: This was a post-hoc analysis of a prospective observational cohort study of patients admitted to the intensive care unit between July 2006 and January 2008 at a tertiary care medical center. The primary endpoint was the incidence of VTE during ICU stay up to 30 days. Secondary endpoint was overall 30-day hospital mortality. Propensity score was used to adjust for clinically and statistically relevant variables.

Results: Of the 798 patients included in the original study, 123 patients (15.4%) received statins during their ICU stay. Survival analysis for VTE risk showed that statin therapy was not associated with a reduction of VTE incidence (crude hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.28-1.54, P=0.33 and adjusted HR 0.63, 95% CI 0.25-1.57, P=0.33). Furthermore, survival analysis for hospital mortality showed that statin therapy was not associated with a reduction in hospital mortality (crude HR 1.26, 95% CI 0.95-1.68, P=0.10 and adjusted HR 0.98, 95% CI 0.72-1.36, P=0.94).

Conclusion: Our study showed no statistically significant association between statin therapy and VTE risk in critically ill patients. This question needs to be further studied in randomized control trials.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology PHARMACOLOGY & PHARMACY-TOXICOLOGY
CiteScore
4.40
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊介绍: BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信